ArticleCell death discovery2026
Hepatocyte TonEBP promotes metabolic stress-induced hepatic fibroinflammation involving transcriptional activation of ELR⁺ CXC chemokines.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH), a progressive stage of metabolic dysfunction-associated steatotic liver disease (MASLD), is characterized by liver inflammation, fibrosis, and hepatocyte injury. Despite its clinical relevance, the molecular mechanisms linking metabolic stress to hepatic fibroinflammation remain poorly understood. In this study, we identify Tonicity-Responsive Enhancer-Binding Protein (TonEBP) as a key stress-responsive transcription factor that mediates the link between metabolic overload and liver inflammation in non-malignant hepatocytes. Using hepatocyte-specific TonEBP knockout (HKO) mice, we demonstrate that TonEBP deletion reduces liver injury, inflammation, and fibrosis in MASH and steatosis models. Mechanistically, TonEBP recruits nuclear factor-κB (NF-κB) to ELR⁺ CXC chemokine gene promoters, promoting neutrophil and macrophage recruitment. These findings underscore the hepatocyte-intrinsic TonEBP/NF-κB axis as a critical driver of immune cell infiltration and fibroinflammation in MASLD progression, revealing its pivotal role in the pathophysiology of liver disease. By highlighting this axis, we provide new insight into the molecular mechanisms that govern the transition from steatosis to steatohepatitis, emphasizing the importance of TonEBP in regulating inflammatory pathways within hepatocytes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.